Key Points
- Director Sven Wehrwein sold shares: Wehrwein disposed of 5,033 shares on Nov. 24 at $37.32 ($187,831.56) and 4,967 shares on Nov. 25 at $38.00, cutting his stake by 12.77% to 34,374 shares.
- Quarterly results mixed: AtriCure beat EPS estimates (reported ($0.01) vs. consensus ($0.11)) and revenue rose 15.8% to $134.27M, but the company reaffirmed negative FY2025 guidance of roughly -$0.26 to -$0.23 per share.
- Analyst sentiment positive overall: Ten analysts rate the stock a Buy vs. one Sell, consensus is a "Moderate Buy" with an average target of $52.22 and upgraded targets such as Canaccord's $64.00.
AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) Director Sven Wehrwein sold 5,033 shares of the business's stock in a transaction on Monday, November 24th. The stock was sold at an average price of $37.32, for a total value of $187,831.56. Following the completion of the transaction, the director directly owned 34,374 shares of the company's stock, valued at approximately $1,282,837.68. This trade represents a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Sven Wehrwein also recently made the following trade(s):
- On Tuesday, November 25th, Sven Wehrwein sold 4,967 shares of AtriCure stock. The shares were sold at an average price of $38.00, for a total transaction of $188,746.00.
AtriCure Price Performance
AtriCure stock opened at $36.03 on Thursday. The firm's 50-day moving average is $35.14 and its two-hundred day moving average is $34.22. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.94 and a quick ratio of 2.83. The stock has a market capitalization of $1.79 billion, a P/E ratio of -59.06 and a beta of 1.56. AtriCure, Inc. has a 12-month low of $28.29 and a 12-month high of $43.11.
AtriCure (NASDAQ:ATRC - Get Free Report) last released its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.10. The firm had revenue of $134.27 million during the quarter, compared to analysts' expectations of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. AtriCure's revenue for the quarter was up 15.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260--0.230 EPS. Equities analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current year.
Analysts Set New Price Targets
A number of analysts recently weighed in on the stock. Canaccord Genuity Group upped their price target on shares of AtriCure from $53.00 to $64.00 and gave the stock a "buy" rating in a research report on Thursday, October 30th. Wall Street Zen upgraded AtriCure from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Citigroup reissued a "market outperform" rating on shares of AtriCure in a research report on Thursday, October 30th. Needham & Company LLC lifted their price target on shares of AtriCure from $44.00 to $45.00 and gave the stock a "buy" rating in a research note on Wednesday, July 30th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AtriCure in a report on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $52.22.
Get Our Latest Report on AtriCure
Institutional Investors Weigh In On AtriCure
Large investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of AtriCure by 170.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,196,914 shares of the medical device company's stock worth $70,872,000 after buying an additional 1,385,544 shares during the period. Nuveen LLC bought a new position in shares of AtriCure in the first quarter worth $30,666,000. Wellington Management Group LLP increased its holdings in shares of AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company's stock valued at $151,296,000 after purchasing an additional 322,818 shares during the period. Osterweis Capital Management Inc. acquired a new stake in AtriCure in the first quarter worth about $9,536,000. Finally, Millennium Management LLC grew its position in AtriCure by 79.2% in the 1st quarter. Millennium Management LLC now owns 623,323 shares of the medical device company's stock valued at $20,108,000 after buying an additional 275,487 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company's stock.
About AtriCure
(
Get Free Report)
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
